Impact of the Implementation of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 622
- 试验地点
- 12
- 主要终点
- Number of patients with at least one preventable medication error
研究概览
简要总结
The primary objective of this study is to evaluate the impact of the implementation of collaborative pharmaceutical care on drug support at admission for patients 65 years of age and older.
This is a cluster-randomized study with a stepped-wedge design. Clusters correspond to participating centers. A randomly selected center is crossed-over into the intervention every fifteen days after the start of inclusions.
详细描述
The secondary objectives are to evaluate:
A. The potential and observed clinical impact of the implementation of collaborative pharmaceutical care.
B. The acceptance rate of pharmaceutical interventions during collaborative pharmaceutical care.
C. Avoidable costs related to the consumption of care generated by the occurrence of serious adverse drug reactions.
D. The satisfaction of health professionals concerning the transfer of information on the patient's drug therapy carried out as part of collaborative pharmaceutical care.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient or his/her legal representative was informed about the study
- •The patient is admitted as an in-patient to one of the participating hospitals
- •The patient is available for 3 months of follow-up
排除标准
- •The subject is participating in another drug study
- •The subject is under judicial protection
- •It is impossible to correctly inform the patient or his/her legal representative
- •The patient or his/her legal representative refuses to participate in the study
- •The expected life span of the patient is less than the required 3 months of follow-up
- •It is impossible to contact the patient after hospitalisation
- •Hospitalizatin for longer than 21 days
结局指标
主要结局
Number of patients with at least one preventable medication error
时间窗: Phase 2 (maximum 105 days)
Number of patients with at least one preventable medication error not accepted by the prescribing doctor during the interventional phase
次要结局
- Readmission rate for in-patient hospitalization(90 days after hospital discharge (expected maximum of 21 days of hospitalization))
- Number of patients at high risk for adverse drug events(Day 1 (medical prescription at hospital admission))
- Acceptance rate of pharmaceutical interventions during collaborative interview.(Day 1, hospital admission)
- Preventable medication error rate(Day 1 (medical prescription at hospital admission))
- Mortality rate(90 days after hospital discharge (expected maximum of 21 days of hospitalization))
- Length of hospital stay(hospital discharge (expected maximum of 21 days of hospitalization))
- Avoided costs related to the occurrence of medication errors (criticality 3)(90 days after hospital discharge (expected maximum of 21 days of hospitalization))
- Satisfaction questionnaire (for health care professionals) on the implementation of collaborative pharmaceutical care(End of study (expected at 195 days))